CMV program - Spinoff Redvax sold to Pfizer
Redbiotec has successfully developed a CMV vaccine program based on its rePAX® technology. This program was sold to Pfizer. See Pfizer press release, January 5 2014. Pfizer press release.
“Through the acquisition of the Redvax innovative CMV vaccine platform and expertise we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children,” said Kathrin U. Jansen, a senior vice president of Pfizer.
See also investor statement Redalpine blog.
New focus: Herpesviruses, Influenza and exploratory projects
Redbiotec is participant of an EU program targeting a universal Influenza vaccine.
After the successful transaction with Pfizer, in which Redbiotec’s spinoff Redvax GmbH was sold, Redbiotec has now moved in further herpesvirus fields such as HSV-2.
Beyond the vaccine activities Redbiotec is currently exploring opportunities for the application of its rePAX® platform int the area of pain and microorganisms.